Research output per year
Research output per year
Personal profile
Biography
Andy Redfern is Associate Professor of Medical Oncology at the University of Western Australia, Associate Director for Clinical Strategy at Harry Perkins Institute of Medical Research, Consultant Medical Oncologist at the Fiona Stanley Hospital, Perth, and Medical Director of Linear Clinical Research specialising in early phase human trials.
Beyond a clinical practice treating breast and urological cancers, Andy is principal investigator for a range of clinical trials across all phases and has a portfolio of translational research initiatives. His research interests centre around growth signalling and mechanisms of chemotherapy and hormone therapy resistance in cancer, differentiation and EMT in cancer progression, tumour-stroma interactions and Indigenous cancer biology.
Andy is also chairman and lead clinician of the State Breast Cancer Collaborative and is on scientific advisory boards for the Cancer Council of Western Australia and the Australasian Breast Cancer Trials Group.
Research expertise keywords
- cancer growth signalling
- chemotherapy resistance
- hormone therapy resistance
- cancer progression
- tumour-stroma interactions
Fingerprint
Dive into the research topics where Andrew Redfern is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Network
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
89 Zirconium-labelled girentuximab (89 Zr-TLX250) PET in Urothelial Cancer Patients (ZiPUP): Protocol for a phase i trial of a novel staging modality for urothelial carcinoma
Al-Zubaidi, M., Viswambaram, P., McCombie, S., Liow, E., Lenzo, N., Ferguson, T., Redfern, A. D., Gauci, R. & Hayne, D., 15 Apr 2022, In: BMJ Open. 12, 4, e060478.Research output: Contribution to journal › Article › peer-review
Open Access -
[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial
TheraP Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group, Francis, R. J. & Redfern, A. D., 27 Feb 2021, In: The Lancet. 397, 10276, p. 797-804 8 p.Research output: Contribution to journal › Article › peer-review
144 Citations (Web of Science) -
A phase I open label dose-escalation study to evaluate the tolerability, safety and immunological efficacy of sub-urothelial durvalumab injection in adults with muscle-invasive or high-risk non-muscle-invasive bladder cancer (SUBDUE-1, SUB-urothelial DUrvalumab injection-1 study): clinical trial protocol
Moe, A., Liow, E., Redfern, A., Swarbrick, N., Ferguson, T., Davis, I. D. & Hayne, D., 6 May 2021, (E-pub ahead of print) In: BJU International.Research output: Contribution to journal › Article › peer-review
-
Capecitabine for hormone receptor-positive versus hormone receptor-negative breast cancer
Hoon, S. N., Lau, P. K. H., White, A. M., Bulsara, M. K., Banks, P. D. & Redfern, A. D., 26 May 2021, In: Cochrane Database of Systematic Reviews. 2021, 5, CD011220.Research output: Contribution to journal › Review article › peer-review
2 Citations (Scopus) -
Measuring and Modelling the Epithelial- Mesenchymal Hybrid State in Cancer: Clinical Implications
Jolly, M. K., Murphy, R. J., Bhatia, S., Whitfield, H. J., Redfern, A., Davis, M. J. & Thompson, E. W., 26 Apr 2021, (E-pub ahead of print) In: Cells Tissues Organs. 24 p.Research output: Contribution to journal › Review article › peer-review
5 Citations (Scopus)
-
ANZUP Below The Belt Grant 2021
McCombie, S., Hayne, D., Redfern, A., Spalding, L., Swarbrick, N. & Law, N.
Australian and New Zealand Urogenital and Prostate Cancer Trials Group
15/10/21 → 15/10/23
Project: Research
-
NHMRC Equipment Grant Scheme 2021
Leedman, P., Yeoh, G., Forrest, A., Redfern, A., Lister, R., Hamzah, J., Flematti, G., Mutsaers, S., Nowak, A., Choi, Y. S. & Chooi, H.
National Health & Medical Research Council NHMRC
29/06/21 → 29/06/22
Project: Research
-
: Identifying targets on myeloid cells to design personalized combination immunotherapies for triple negative breast cancer
1/01/21 → 31/12/23
Project: Research
-
Reversing epithelial to mesenchymal transition by targeted epigenetic editing in breast cancer
Blancafort, P., Gersbach, C., Thompson, E., Swaminatha Iyer, K., Rots, M., Redfern, A., Chaffer, C. & Cursons, J.
National Health & Medical Research Council NHMRC
1/01/18 → 31/12/22
Project: Research